SCHEMBL30325839

SCHEMBL30325839

C=CC(=O)Nc1ccc(-n2nc(-c3ccc(Oc4nccc(C)n4)c(OC)c3)c3c(N)ncnc32)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 2/20 0.48
▸ FGFR2 P21802 2/20 0.48
▸ FGFR3 P22607 2/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ FGFR4 P22455 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ SRC P12931 9/20 0.45
▸ ITK Q08881 1/20 0.43
▸ BTK Q06187 1/20 0.43
▸ EGFR P00533 8/20 0.43
▸ PIK3CD O00329 7/20 0.43
▸ ABL1 P00519 7/20 0.43
▸ HCK P08631 7/20 0.43
▸ PIK3CA P42336 7/20 0.43
▸ PIK3CB P42338 7/20 0.43
▸ MTOR P42345 7/20 0.43
▸ PIK3CG P48736 7/20 0.43
▸ EPHB4 P54760 7/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22675919 0.84 FGFR1 (0.68) FGFR1FGFR2FGFR3CYP3A4CYP2D6
SCHEMBL30303580 0.84 FGFR1 (0.68) FGFR1FGFR2FGFR3CYP3A4CYP2D6
SCHEMBL31213977 0.83 FGFR1 (0.65) FGFR1FGFR2FGFR3CYP3A4CYP2D6
SCHEMBL31213851 0.83 CYP3A4 (0.43) FGFR1FGFR2FGFR3CYP3A4CYP2D6
SCHEMBL30739403 0.81 CYP3A4 (0.46) FGFR1FGFR2FGFR3CYP3A4CYP2D6
SCHEMBL29178890 0.81 CYP3A4 (0.46) FGFR1FGFR2FGFR3CYP3A4CYP2D6
SCHEMBL31213863 0.79 FGFR1 (0.53) FGFR1FGFR2FGFR3CYP3A4CYP2D6
SCHEMBL30325654 0.78 FGFR4 (0.51) FGFR1FGFR2FGFR3CYP3A4CYP2D6
SCHEMBL31213873 0.77 FGFR4 (0.57) FGFR1FGFR2FGFR3CYP3A4CYP2D6
SCHEMBL31213970 0.77 FGFR4 (0.56) FGFR1FGFR2FGFR3CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US claimed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP claimed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO claimed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 — — US disclosed
EP-4405358-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H Pharmaceuticals Co., Ltd. (CN) 2024-07-31 — — EP disclosed
WO-2023046117-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2023-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR1, FGFR3, FGFR4 FGFR1 1/4885FGFR2 4/4885FGFR3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback